Cargando…
Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium
Background: Routine human papillomavirus (HPV) immunization in Belgium is currently regionally managed, with school-aged girls receiving the 9-valent HPV (9vHPV) vaccine in Flanders and Wallonia-Brussels with a national catch-up program for females only. This study will assess whether expanding thes...
Autores principales: | Simoens, Steven, Bento-Abreu, Andre, Merckx, Barbara, Joubert, Sophie, Vermeersch, Steve, Pavelyev, Andrew, Varga, Stefan, Morais, Edith |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072375/ https://www.ncbi.nlm.nih.gov/pubmed/33912045 http://dx.doi.org/10.3389/fphar.2021.628434 |
Ejemplares similares
-
Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland
por: Kind, André B., et al.
Publicado: (2020) -
Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong
por: Cheung, Tak Hong, et al.
Publicado: (2023) -
The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong
por: Cheung, Tak Hong, et al.
Publicado: (2021) -
Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
por: Barbier, Liese, et al.
Publicado: (2022) -
Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis
por: Vandenplas, Yannick, et al.
Publicado: (2021)